The expression of immune checkpoint genes [e.g., PDCD1 (PD1), CD274 (PDL1), CTLA4, LAG3, and HAVCR2 (TIM3)] has been utilized in predicting the response of patients to ICB therapy in a variety of cancers including CC. This evidence concerns the gene CTLA4 and cancer.